Abituzumab(Abituzumab) - 药物靶点：CD51_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Anti-CD51 antigen mAb、Anti-integrin alphaV mAb

+ [3]

靶点

CD51

作用机制

CD51拮抗剂(整合素α-V拮抗剂)、ADCC(抗体依赖的细胞毒作用)

治疗领域

肿瘤消化系统疾病呼吸系统疾病+ [5]

在研适应症-

非在研适应症

晚期恶性实体瘤骨病骨转移癌+ [10]

原研机构

Merck Serono SA

在研机构-

非在研机构

Merck KGaA

EMD Serono, Inc.

SFJ Pharmaceuticals, Inc.

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 9976294H

来源: *****

Sequence Code 15623086L

来源: *****

关联

7

项与 Abituzumab 相关的临床试验

NCT03688230 / Withdrawn临床2期

AMELION: A Randomized, Double Blinded, Phase 2, Efficacy and Safety Study of Abituzumab (EMD 525797) in Combination With Cetuximab and FOLFIRI Versus Placebo in Combination With Cetuximab and FOLFIRI in First-line RAS Wild-type, Left-sided, Metastatic Colorectal Cancer Patients With High ανβ6 Integrin Expression.

The purpose of this study is to evaluate the safety and efficacy of the experimental drug abituzumab (EMD525797) in combination with cetuximab and FOLFIRI in RAS wild-type, left-sided, metastatic colorectal cancer patients with high ανβ6 integrin expression.

开始日期2019-04-01

申办/合作机构

SFJ Pharmaceuticals X, LTD.

[+3]

NCT02745145 / Terminated临床2期

A Phase II, Randomized, Double-blind, Placebo Controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy and Safety of Abituzumab in Subjects With Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)

The purpose of this trial was to compare two doses of abituzumab with placebo and determine whether abituzumab was more effective, safer, would be better tolerated and could provoke better immune response than placebo in the treatment of participants with SSc-ILD who already receive constant doses of mycophenolate.

开始日期2016-05-31

申办/合作机构

EMD Serono Research & Development Institute, Inc.

[+1]

NCT01360840 / Completed临床2期

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)

The primary objective of the trial is to evaluate the clinical anti-tumor activity of EMD 525797 administered as 1-hour intravenous infusion every 3 weeks in terms of progression free survival (PFS) time in subjects with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (mCRPC).

开始日期2011-04-01

申办/合作机构

EMD Serono, Inc.

100 项与 Abituzumab 相关的临床结果

登录后查看更多信息

100 项与 Abituzumab 相关的转化医学

登录后查看更多信息

100 项与 Abituzumab 相关的专利（医药）

登录后查看更多信息

35

项与 Abituzumab 相关的文献（医药）

2023-06-20·Analytical chemistry

Integration of NMR Spectroscopy in an Analytical Workflow to Evaluate the Effects of Oxidative Stress on Abituzumab: Beyond the Fingerprint of mAbs.

Article

作者: Fischer, Christian ; Trovato, Andrea ; Ravera, Enrico ; Baroni, Fabio ; Fragai, Marco ; Angiuoni, Gabriella ; Cerofolini, Linda ; Palinsky, Wolf ; Sacco, Francesca

The assessment of the higher-order structure (HOS) by NMR is a powerful methodology to characterize the structural features of biologics. Forced oxidative stress studies are used to investigate the stability profile, to develop pharmaceutical formulations and analytical methods. Here, the effects of forced oxidative stress by H₂O₂ on the monoclonal antibody Abituzumab have been characterized by a multianalytical approach combining NMR spectroscopy, mass spectrometry, differential scanning calorimetry, surface plasmon resonance, computational tools, and bioassays. This integrated strategy has provided qualitative and semiquantitative characterization of the samples and information at residue level of the effects that oxidation has on the HOS of Abituzumab, correlating them to the loss of the biological activity.

2021-08-01·Clinical & Experimental Metastasis3区 · 医学

CXCL2-CXCR2 axis mediates αV integrin-dependent peritoneal metastasis of colon cancer cells

3区 · 医学

Article

作者: Lepsenyi, Mattias ; Al-Haidari, Amr A ; Syk, Ingvar ; Thorlacius, Henrik ; Algaber, Anwar ; Rahman, Milladur ; Algethami, Nader

AbstractPeritoneal metastasis is an insidious aspect of colorectal cancer. The aim of the present study was to define mechanisms regulating colon cancer cell adhesion and spread to peritoneal wounds after abdominal surgery. Mice was laparotomized and injected intraperitoneally with CT-26 colon carcinoma cells and metastatic noduli in the peritoneal cavity was quantified after treatment with a CXCR2 antagonist or integrin-αV-antibody. CT-26 cells expressed cell surface chemokine receptors CXCR2, CXCR3, CXCR4 and CXCR5. Stimulation with the CXCR2 ligand, CXCL2, dose-dependently increased proliferation and migration of CT-26 cells in vitro. The CXCR2 antagonist, SB225002, dose-dependently decreased CXCL2-induced proliferation and migration of colon cancer cells in vitro. Intraperitoneal administration of CT-26 colon cancer cells resulted in wide-spread growth of metastatic nodules at the peritoneal surface of laparotomized animals. Laparotomy increased gene expression of CXCL2 at the incisional line. Pretreatment with CXCR2 antagonist reduced metastatic nodules by 70%. Moreover, stimulation with CXCL2 increased CT-26 cell adhesion to extracellular matrix (ECM) proteins in a CXCR2-dependent manner. CT-26 cells expressed the αV, β1 and β3 integrin subunits and immunoneutralization of αV abolished CXCL2-triggered adhesion of CT-26 to vitronectin, fibronectin and fibrinogen. Finally, inhibition of the αV integrin significantly attenuated the number of carcinomatosis nodules by 69% in laparotomized mice. These results were validated by use of the human colon cancer cell line HT-29 in vitro. Our data show that colon cancer cell adhesion and growth on peritoneal wound sites is mediated by a CXCL2-CXCR2 signaling axis and αV integrin-dependent adhesion to ECM proteins.

2021-08-01·The Journal of Rheumatology2区 · 医学

STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis–associated Interstitial Lung Disease

2区 · 医学

Article

作者: Wells, Athol U ; Fleuranceau-Morel, Patricia ; Denton, Christopher P ; Tashkin, Donald P ; Khanna, Dinesh ; Vazquez-Mateo, Cristina ; Seibold, James R ; Damian, Doris ; Wax, Stephen

ObjectiveTo investigate the effects of abituzumab in systemic sclerosis–associated interstitial lung disease (SSc-ILD).MethodsSTRATUS was a phase II, double-blind, parallel-group, multicenter trial (ClinicalTrials.gov: NCT02745145). Adults (≤ 75 yrs) with SSc-ILD on stable mycophenolate were randomized (2:2:1) to receive intravenous abituzumab 1500 mg, abituzumab 500 mg, or placebo every 4 weeks for 104 weeks. The primary endpoint was the annual rate of change in absolute forced vital capacity.ResultsSTRATUS was terminated prematurely due to slow enrollment (n = 75 screened, n = 24 randomized), precluding robust analysis of efficacy. Abituzumab was well tolerated; no new safety signals were detected.ConclusionFurther investigation of abituzumab for treatment of SSc-ILD is required.

100 项与 Abituzumab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Abituzumab	-	DB12775

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
KRAS 野生型结直肠癌	临床2期	以色列	Merck KGaA	2009-10-01
KRAS 野生型结直肠癌	临床2期	塞浦路斯	Merck KGaA	2009-10-01
KRAS 野生型结直肠癌	临床2期	捷克	Merck KGaA	2009-10-01
KRAS 野生型结直肠癌	临床2期	西班牙	Merck KGaA	2009-10-01
KRAS 野生型结直肠癌	临床2期	俄罗斯	Merck KGaA	2009-10-01
KRAS 野生型结直肠癌	临床2期	波兰	Merck KGaA	2009-10-01
KRAS 野生型结直肠癌	临床2期	保加利亚	Merck KGaA	2009-10-01
KRAS 野生型结直肠癌	临床2期	英国	Merck KGaA	2009-10-01
KRAS 野生型结直肠癌	临床2期	希腊	Merck KGaA	2009-10-01
KRAS 野生型结直肠癌	临床2期	德国	Merck KGaA	2009-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02745145 (CTgov)	临床2期	系统性硬化相关的间质性肺病	24	Placebo (Placebo)	積壓醖範選網願獵齋願(襯鑰願襯壓構夢鹹糧網) = 襯夢遞網膚淵夢夢鹽積構壓壓齋願遞選蓋鬱糧 (簾廠衊夢鹹積構製窪壓, 齋鹽鑰衊繭鏇衊糧鏇艱 ~ 築簾獵構鑰顧製淵構鑰) 更多	-	2019-06-18
				Abituzumab 500 mg (Abituzumab 500 mg)	觸選鏇艱願選鏇觸蓋製(構糧繭夢製築齋窪製觸) = 簾遞齋觸築齋繭積窪壓簾襯鏇繭醖壓壓顧選艱 (鹹簾選網簾衊襯鏇鑰鏇, 願積繭願繭構觸簾觸願 ~ 鏇鬱廠積製醖網鏇淵製) 更多
NCT01008475 (Poseidon, ESMO2018)	临床1/2期	转移性结直肠癌	232	Abituzumab 1000mg + irinotecan+cetuximab	(構遞鑰構鹽壓獵製憲壓) = 範餘積網蓋鏇蓋構願遞齋遞築壓膚獵淵餘夢淵 (觸艱遞簾積鹽遞憲膚蓋 ) 更多	积极	2018-10-21
				Irinotecan+cetuximab	(構遞鑰構鹽壓獵製憲壓) = 範鹽糧願選築鹽憲衊鑰齋遞築壓膚獵淵餘夢淵 (觸艱遞簾積鹽遞憲膚蓋 ) 更多
NCT00958477 (CTgov)	临床1期	去势抵抗性前列腺癌 \| 骨病 \| 骨转移癌	26	EMD 525797 (EMD 525797 250 mg)	夢築壓廠簾糧夢窪鏇繭(齋夢鹽構衊衊憲範積廠) = 憲鑰淵艱壓獵網鹽憲願鏇憲鏇觸膚簾膚獵製淵 (鏇願觸獵廠積鹹廠鑰鹽, 範願糧選憲蓋憲廠觸鹽 ~ 窪淵遞窪繭鹽觸網願膚) 更多	-	2017-08-02
				EMD 525797 (EMD 525797 500 mg)	夢築壓廠簾糧夢窪鏇繭(齋夢鹽構衊衊憲範積廠) = 衊鑰醖淵顧網遞餘鹽遞鏇憲鏇觸膚簾膚獵製淵 (鏇願觸獵廠積鹹廠鑰鹽, 餘選蓋繭構顧鏇築範鏇 ~ 鑰築壓鹽膚遞廠餘淵築) 更多
NCT01327313 (CTgov)	临床1期	神经梅毒 \| 晚期恶性实体瘤	27	EMD525797 (EMD525797 500 mg)	齋壓襯願襯積夢淵繭餘(願鑰鑰鏇鏇遞簾壓衊憲) = 鏇廠遞廠繭鬱蓋齋獵夢構製繭積壓壓選淵艱觸 (齋遞網築鏇糧襯鏇簾築, 鹹願築製襯鑰夢觸顧衊 ~ 壓壓鏇夢構繭壓簾遞醖) 更多	-	2016-05-13
				EMD525797 (EMD525797 1000 mg)	齋壓襯願襯積夢淵繭餘(願鑰鑰鏇鏇遞簾壓衊憲) = 築觸鏇窪簾衊醖積選衊構製繭積壓壓選淵艱觸 (齋遞網築鏇糧襯鏇簾築, 襯艱構壓憲廠壓淵餘衊 ~ 艱憲願網蓋廠築窪繭壓) 更多
NCT01008475 (POSEIDON, CTgov)	临床1/2期	KRAS 野生型结直肠癌 \| 转移性结直肠癌	232	Cetuximab+EMD 525797 500 mg+Irinotecan	積鹽夢醖壓襯憲簾網淵(餘憲鏇鏇網淵簾淵遞醖) = 鹽餘淵鬱製網選鏇遞遞積遞鬱製鹽鬱鬱選範網 (繭憲網鹽鏇蓋齋夢鑰積, 觸鹽選範憲憲鑰網構願 ~ 糧鏇鑰窪壓糧製窪鹽遞) 更多	-	2016-03-30
NCT00848510 (CTgov)	临床1期	肝转移 \| 卵巢癌 \| 结直肠癌	41	Abituzumab (Abituzumab 250 mg)	壓襯築鑰製構窪選淵憲(襯鹹鹽網壓築獵鑰繭鹽) = 鏇糧製襯鏇膚齋網鏇構襯衊積廠鏇醖壓憲願鏇 (範願獵憲製構齋獵網餘, 築顧餘憲鏇遞艱膚製鑰 ~ 鑰鬱壓積構壓鑰艱簾淵) 更多	-	2015-12-14
				Abituzumab (Abituzumab 500 mg)	壓襯築鑰製構窪選淵憲(襯鹹鹽網壓築獵鑰繭鹽) = 網窪餘範廠夢壓製遞願襯衊積廠鏇醖壓憲願鏇 (範願獵憲製構齋獵網餘, 遞憲選壓鏇觸餘餘襯觸 ~ 廠顧廠鬱繭觸簾糧糧繭) 更多
NCT01360840 (PERSEUS, CTgov)	临床2期	转移性去势抵抗性前列腺癌 \| 转移性前列腺癌	180	Standard of Care (SoC)+EMD 525797 (EMD 525797 750 mg + SoC)	蓋糧衊糧憲膚淵膚夢齋(窪醖網壓艱觸醖蓋衊鬱) = 觸觸鏇築遞顧構顧願鏇餘淵顧構網蓋構製醖餘 (構膚遞鏇夢衊醖餘遞餘, 膚廠鹽築襯夢簾夢獵範 ~ 鬱廠壓餘獵繭窪夢繭糧) 更多	-	2015-12-14
				Standard of Care (SoC)+EMD 525797 (EMD 525797 1500 mg + SoC)	蓋糧衊糧憲膚淵膚夢齋(窪醖網壓艱觸醖蓋衊鬱) = 獵簾鑰遞獵築製壓蓋鹹餘淵顧構網蓋構製醖餘 (構膚遞鏇夢衊醖餘遞餘, 膚夢網鹽膚衊淵遞築壓 ~ 積製積鏇窪膚窪鏇憲獵) 更多
NCT01008475 (POSEIDON, Pubmed \| Ann Oncol)	临床1/2期	KRAS 野生型结直肠癌	232	Abituzumab 500 mg	(範積糧獵製憲憲鹹醖齋) = A trend toward improved OS was observed 簾構範築鹽鹽憲繭憲鹹 (餘夢襯製製選範壓糧蓋 )	不佳	2015-01-01
				Abituzumab 1000 mg
NCT01008475 (POSEIDON, Pubmed)	临床1/2期	KRAS 野生型结直肠癌	232	Abituzumab 500mg	(鑰觸淵夢醖願蓋構衊蓋) = A trend toward improved OS was observed 醖獵膚願壓繭淵顧餘繭 (範簾簾繭淵簾醖構鬱鬱 )	不佳	2015-01-01
				Abituzumab 1000mg
NCT01008475 (POSEIDON, ESMO_GI2014)	临床1/2期	KRAS 野生型结直肠癌二线 KRAS wild-type	216	Abituzumab 500 mg	(淵憲製齋襯網廠簾鬱範) = 願觸醖鏇齋顧積鹹廠餘鏇膚鏇餘壓憲繭鹹觸製 (齋積鹽餘範鹹齋齋顧繭 ) 更多	不佳	2014-06-25
				Abituzumab 1000 mg	(淵憲製齋襯網廠簾鬱範) = 構鬱鹽壓鹽憲鬱簾網遞鏇膚鏇餘壓憲繭鹹觸製 (齋積鹽餘範鹹齋齋顧繭 ) 更多